法尼醇X受体拮抗剂及其虚拟筛选方法和应用
By using virtual screening technology to identify small molecule FXR antagonists, the problem of the lack of effective drugs for the treatment of NASH in existing technologies has been solved. This has enabled the discovery of efficient and economical FXR antagonists with significant therapeutic effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGDONG LONGRUI BIOTECHNOLOGY CO LTD
- Filing Date
- 2023-01-12
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack effective drug treatments for non-alcoholic steatohepatitis (NASH). FXR agonists have side effects, research on FXR antagonists is lagging, and traditional drug development is time-consuming and expensive.
Using virtual screening technology and molecular docking software, small molecule compounds with good binding ability to FXR were screened out. In vitro antagonistic activity tests were conducted, and 12 compounds with strong FXR antagonistic activity were found.
The selected compounds exhibit significant FXR antagonistic activity, which can effectively treat diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), avoiding the side effects of FXR agonists and shortening the drug development cycle and cost.
Smart Images
Figure CN116130027B_ABST